Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy ...

Chardan initiated coverage of Mind Medicine (MNMD) with a Buy rating and $20 price target The firm cites the potential of the company’s lead ...

Leerink Partners started coverage on Mind Medicine (MindMed) in a report on Monday, October 14th. They issued an “outperform” rating and a $20.00 price objective for the company. Leerink ...

Oppenheimer analyst Francois Brisebois maintained a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $7.40.

The projected annual revenue for Mind Medicine is 0MM. The projected annual non-GAAP EPS is -3.18. Commodore Capital holds 8,000K shares representing 10.91% ownership of the company. In its prior ...

NEW YORK, December 11, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...

grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 8.3% during the third quarter, Holdings Channel reports. The firm owned 602,544 shares of the company ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), with a market capitalization of $525 million, is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapies for ...